Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland.
dc.contributor.author | Vickers, I | |
dc.contributor.author | Fitzgerald, M | |
dc.contributor.author | Murchan, S | |
dc.contributor.author | Cotter, S | |
dc.contributor.author | O'Flanagan, D | |
dc.contributor.author | Cafferkey, M | |
dc.contributor.author | Humphreys, H | |
dc.date.accessioned | 2011-06-30T15:11:40Z | |
dc.date.available | 2011-06-30T15:11:40Z | |
dc.date.issued | 2011-05 | |
dc.identifier.citation | Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland. 2011, 139 (5):783-90 Epidemiol. Infect. | en |
dc.identifier.issn | 1469-4409 | |
dc.identifier.pmid | 20642870 | |
dc.identifier.doi | 10.1017/S0950268810001743 | |
dc.identifier.uri | http://hdl.handle.net/10147/135011 | |
dc.description.abstract | The 7-valent pneumococcal conjugate vaccine (PCV7) was included in the routine infant immunization schedule in Ireland in September 2008. We determined the serotype of 977 S. pneumoniae isolates causing invasive disease between 2000-2002 and 2007-2008, assessed for the presence of the recently described serotype 6C and determined the susceptibility of isolates during 2007-2008 to penicillin and cefotaxime. Serotype 14 was the most common serotype during both periods and 7·7% of isolates previously typed as serotype 6A were serotype 6C. During 2000-2002 and 2007-2008, PCV7 could potentially have prevented 85% and 74% of invasive pneumococcal disease in the target population (i.e. children aged <2 years), respectively. The level of penicillin non-susceptibility was 17% in 2007-2008. Ongoing surveillance of serotypes is required to determine the impact of PCV7 in the Irish population and to assess the potential of new vaccines with expanded valency. | |
dc.language.iso | en | en |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/20642870 | en |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Anti-Bacterial Agents | |
dc.subject.mesh | Bacterial Typing Techniques | |
dc.subject.mesh | Cefotaxime | |
dc.subject.mesh | Child | |
dc.subject.mesh | Child, Preschool | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Infant | |
dc.subject.mesh | Infant, Newborn | |
dc.subject.mesh | Ireland | |
dc.subject.mesh | Male | |
dc.subject.mesh | Microbial Sensitivity Tests | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Penicillins | |
dc.subject.mesh | Pneumococcal Infections | |
dc.subject.mesh | Pneumococcal Vaccines | |
dc.subject.mesh | Serotyping | |
dc.subject.mesh | Streptococcus pneumoniae | |
dc.subject.mesh | Vaccination | |
dc.subject.mesh | Young Adult | |
dc.subject.mesh | beta-Lactam Resistance | |
dc.title | Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland. | en |
dc.type | Article | en |
dc.contributor.department | Epidemiology and Molecular Biology Unit and Irish Meningococcal and Meningitis Reference Laboratory, Children's University Hospital, Dublin, Ireland. imelda.vickers@cuh.ie | en |
dc.identifier.journal | Epidemiology and infection | en |
dc.description.province | Leinster | |
html.description.abstract | The 7-valent pneumococcal conjugate vaccine (PCV7) was included in the routine infant immunization schedule in Ireland in September 2008. We determined the serotype of 977 S. pneumoniae isolates causing invasive disease between 2000-2002 and 2007-2008, assessed for the presence of the recently described serotype 6C and determined the susceptibility of isolates during 2007-2008 to penicillin and cefotaxime. Serotype 14 was the most common serotype during both periods and 7·7% of isolates previously typed as serotype 6A were serotype 6C. During 2000-2002 and 2007-2008, PCV7 could potentially have prevented 85% and 74% of invasive pneumococcal disease in the target population (i.e. children aged <2 years), respectively. The level of penicillin non-susceptibility was 17% in 2007-2008. Ongoing surveillance of serotypes is required to determine the impact of PCV7 in the Irish population and to assess the potential of new vaccines with expanded valency. |